The anticoagulant warfarin, administered in small doses and over an extended period, appears to be very effective in reducing the risk of blood clots, US researchers have announced.
The National Heart, Lung and Blood Institute had encountered “such a high degree of benefit to the patients without significant adverse effects” that it decided to cut short the research.
A four-year study showed that the use of warfarin – a prolonged action anticoagulant from the K group of antivitamins – reduced deep vein thrombosis and pulmonary embolism by 64 percent.
AFP